TY - JOUR AU - Jares, P. AU - Colomer, D. AU - Campo, E. PY - 2007 DA - 2007// TI - Genetic and molecular pathogenesis of mantle cell lymphoma. Perspectives for new targeted therapeutics JO - Nat Rev Cancer VL - 7 UR - https://doi.org/10.1038/nrc2230 DO - 10.1038/nrc2230 ID - Jares2007 ER - TY - JOUR AU - Jares, P. AU - Colomer, D. AU - Campo, E. PY - 2012 DA - 2012// TI - Molecular pathogenesis of mantle cell lymphoma JO - J Clin Invest VL - 122 UR - https://doi.org/10.1172/JCI61272 DO - 10.1172/JCI61272 ID - Jares2012 ER - TY - JOUR AU - Yu, W. AU - Denu, R. A. AU - Krautkramer, K. A. AU - Grindle, K. M. AU - Yang, D. T. AU - Asimakopoulos, F. PY - 2016 DA - 2016// TI - Loss of SIRT3 provides growth advantage for B cell malignancies JO - J Biol Chem VL - 291 UR - https://doi.org/10.1074/jbc.M115.702076 DO - 10.1074/jbc.M115.702076 ID - Yu2016 ER - TY - JOUR AU - Jackson, S. P. AU - Bartek, J. PY - 2009 DA - 2009// TI - The DNA-damage response in human biology and disease JO - Nature VL - 461 UR - https://doi.org/10.1038/nature08467 DO - 10.1038/nature08467 ID - Jackson2009 ER - TY - JOUR AU - Beà, S. AU - Valdés-Mas, E. AU - Navarro, A. AU - Salaverria, I. AU - Martín-Garcia, D. AU - Jares, P. PY - 2013 DA - 2013// TI - Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma JO - Proc Natl Acad Sci U S A VL - 110 UR - https://doi.org/10.1073/pnas.1314608110 DO - 10.1073/pnas.1314608110 ID - Beà2013 ER - TY - JOUR AU - Greiner, T. C. AU - Dasgupta, C. AU - Ho, V. V. AU - Weisenburger, D. D. AU - Smith, L. M. AU - Lynch, J. C. PY - 2006 DA - 2006// TI - Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma JO - Proc Natl Acad Sci U S A VL - 103 UR - https://doi.org/10.1073/pnas.0510441103 DO - 10.1073/pnas.0510441103 ID - Greiner2006 ER - TY - JOUR AU - Pérez-Galán, P. AU - Dreyling, M. AU - Wiestner, A. PY - 2011 DA - 2011// TI - Mantle cell lymphoma. Biology, pathogenesis, and the molecular basis of treatment in the genomic era JO - Blood VL - 117 UR - https://doi.org/10.1182/blood-2010-04-189977 DO - 10.1182/blood-2010-04-189977 ID - Pérez-Galán2011 ER - TY - JOUR AU - Chen, R. AU - Sanchez, J. AU - Rosen, S. T. PY - 2016 DA - 2016// TI - Clinical management updates in mantle cell lymphoma JO - Oncology VL - 30 ID - Chen2016 ER - TY - JOUR AU - Baumann, U. AU - Fernández-Sáiz, V. AU - Rudelius, M. AU - Lemeer, S. AU - Rad, R. AU - Knorn, A. M. PY - 2014 DA - 2014// TI - Disruption of the PRKCD-FBXO25-HAX-1 axis attenuates the apoptotic response and drives lymphomagenesis JO - Nat Med VL - 20 UR - https://doi.org/10.1038/nm.3740 DO - 10.1038/nm.3740 ID - Baumann2014 ER - TY - JOUR AU - Meissner, B. AU - Kridel, R. AU - Lim, R. S. AU - Rogic, S. AU - Tse, K. AU - Scott, D. W. PY - 2013 DA - 2013// TI - The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma JO - Blood VL - 121 UR - https://doi.org/10.1182/blood-2013-01-478834 DO - 10.1182/blood-2013-01-478834 ID - Meissner2013 ER - TY - JOUR AU - Jones, R. J. AU - Bjorklund, C. C. AU - Baladandayuthapani, V. AU - Kuhn, D. J. AU - Orlowski, R. Z. PY - 2012 DA - 2012// TI - Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA JO - Mol Cancer Ther VL - 11 UR - https://doi.org/10.1158/1535-7163.MCT-12-0135 DO - 10.1158/1535-7163.MCT-12-0135 ID - Jones2012 ER - TY - JOUR AU - Moros, A. AU - Bustany, S. AU - Cahu, J. AU - Saborit-Villarroya, I. AU - Martínez, A. AU - Colomer, D. PY - 2014 DA - 2014// TI - Antitumoral activity of lenalidomide in in vitro and in vivo models of mantle cell lymphoma involves the destabilization of cyclin D1/p27KIP1 complexes JO - Clin Cancer Res VL - 20 UR - https://doi.org/10.1158/1078-0432.CCR-13-1569 DO - 10.1158/1078-0432.CCR-13-1569 ID - Moros2014 ER - TY - STD TI - Cahu J, Sola B. A sensitive method to quantify senescent cancer cells. J Vis Exp. 2013; doi:10.3791/50494. ID - ref13 ER - TY - JOUR AU - Vlashi, E. AU - Kim, K. AU - Lagadec, C. AU - Donna, L. D. AU - McDonald, J. T. AU - Eghbali, M. PY - 2009 DA - 2009// TI - In vivo imaging, tracking, and targeting of cancer stem cells JO - J Natl Cancer Inst VL - 101 UR - https://doi.org/10.1093/jnci/djn509 DO - 10.1093/jnci/djn509 ID - Vlashi2009 ER - TY - JOUR AU - Putters, J. AU - Slotman, J. A. AU - Gerlach, J. P. AU - Strous, G. J. PY - 2011 DA - 2011// TI - Specificity, location and function of βTrCP isoforms and their splice variants JO - Cell Signal VL - 23 UR - https://doi.org/10.1016/j.cellsig.2010.11.015 DO - 10.1016/j.cellsig.2010.11.015 ID - Putters2011 ER - TY - JOUR AU - Chen, R. AU - Chubb, S. AU - Cheng, T. AU - Hawtin, R. E. AU - Gandhi, V. AU - Plunkett, W. PY - 2010 DA - 2010// TI - Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line JO - Cancer Res VL - 70 UR - https://doi.org/10.1158/0008-5472.CAN-09-3578 DO - 10.1158/0008-5472.CAN-09-3578 ID - Chen2010 ER - TY - JOUR AU - Jekimovs, C. AU - Bolderson, E. AU - Suraweera, A. AU - Adams, M. AU - O'Byrne, K. J. AU - Richard, D. J. PY - 2014 DA - 2014// TI - Chemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promising JO - Front Oncol VL - 4 UR - https://doi.org/10.3389/fonc.2014.00086 DO - 10.3389/fonc.2014.00086 ID - Jekimovs2014 ER - TY - JOUR AU - Lanigan, F. AU - Geraghty, J. G. AU - Bracken, A. P. PY - 2011 DA - 2011// TI - Transcriptional regulation of cellular senescence JO - Oncogene VL - 30 UR - https://doi.org/10.1038/onc.2011.34 DO - 10.1038/onc.2011.34 ID - Lanigan2011 ER - TY - JOUR AU - Mah, L. J. AU - El-Osta, A. AU - Karagiannis, T. C. PY - 2010 DA - 2010// TI - gammaH2AX: a sensitive molecular marker of DNA damage and repair JO - Leukemia VL - 24 UR - https://doi.org/10.1038/leu.2010.6 DO - 10.1038/leu.2010.6 ID - Mah2010 ER - TY - JOUR AU - Stracker, T. H. PY - 2013 DA - 2013// TI - The ATM signaling network in development and disease JO - Front Genet VL - 4 UR - https://doi.org/10.3389/fgene.2013.00037 DO - 10.3389/fgene.2013.00037 ID - Stracker2013 ER - TY - JOUR AU - Williamson, C. T. AU - Kubota, E. AU - Hamill, J. D. AU - Klimowicz, A. AU - Ye, R. AU - Muzik, H. PY - 2012 DA - 2012// TI - Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53 JO - EMBO Mol Med VL - 4 UR - https://doi.org/10.1002/emmm.201200229 DO - 10.1002/emmm.201200229 ID - Williamson2012 ER - TY - JOUR AU - Aggarwal, P. AU - Lessie, M. D. AU - Lin, D. I. AU - Pontano, L. AU - Gladden, A. B. AU - Nuskey, B. PY - 2007 DA - 2007// TI - Nuclear accumulation of cyclin D1 during S phase inhibits Cul4-dependent Cdt1 proteolysis and triggers p53-dependent DNA rereplication JO - Genes Dev VL - 21 UR - https://doi.org/10.1101/gad.1586007 DO - 10.1101/gad.1586007 ID - Aggarwal2007 ER - TY - JOUR AU - Vaites, L. P. AU - Lian, Z. AU - Lee, E. K. AU - Yin, B. AU - DeMicco, A. AU - Bassing, C. H. AU - Diehl, J. A. PY - 2013 DA - 2013// TI - ATM deficiency augments constitutively nuclear cyclin D1-driven genomic instability and lymphomagenesis JO - Oncogene VL - 33 UR - https://doi.org/10.1038/onc.2012.577 DO - 10.1038/onc.2012.577 ID - Vaites2013 ER - TY - JOUR AU - Alao, J. P. PY - 2007 DA - 2007// TI - The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention JO - Mol Cancer VL - 6 UR - https://doi.org/10.1186/1476-4598-6-24 DO - 10.1186/1476-4598-6-24 ID - Alao2007 ER - TY - JOUR AU - Tchakarska, G. AU - Roussel, M. AU - Troussard, X. AU - Sola, B. PY - 2011 DA - 2011// TI - Cyclin D1 inhibits mitochondrial activity in B cells JO - Cancer Res VL - 71 UR - https://doi.org/10.1158/0008-5472.CAN-10-2564 DO - 10.1158/0008-5472.CAN-10-2564 ID - Tchakarska2011 ER - TY - JOUR AU - Busino, L. AU - Donzelli, M. AU - Chiesa, M. AU - Guardavaccaro, D. AU - Ganoth, D. AU - Dorrello, N. V. PY - 2003 DA - 2003// TI - Degradation of Cdc25A by β-TrCP during S phase and in response to DNA damage JO - Nature VL - 426 UR - https://doi.org/10.1038/nature02082 DO - 10.1038/nature02082 ID - Busino2003 ER - TY - JOUR AU - Kanie, T. AU - Onoyama, I. AU - Matsumoto, A. AU - Yamada, M. AU - Nakatsumi, H. AU - Tateishi, Y. PY - 2012 DA - 2012// TI - Genetic reevaluation of the role of F-box proteins in cyclin D1 degradation JO - Mol Cell Biol VL - 32 UR - https://doi.org/10.1128/MCB.06570-11 DO - 10.1128/MCB.06570-11 ID - Kanie2012 ER - TY - JOUR AU - Wei, S. AU - Yang, H. C. AU - Chuang, H. C. AU - Yang, J. AU - Kulp, S. K. AU - Lu, P. J. PY - 2008 DA - 2008// TI - A novel mechanism by which thiazolidinediones facilitate the proteasomal degradation of cyclin D1 in cancer cells JO - J Biol Chem VL - 283 UR - https://doi.org/10.1074/jbc.M802160200 DO - 10.1074/jbc.M802160200 ID - Wei2008 ER - TY - JOUR AU - Inuzuka, H. AU - Shaik, S. AU - Onoyama, I. AU - Gao, D. AU - Tseng, A. AU - Maser, R. S. PY - 2011 DA - 2011// TI - SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction JO - Nature VL - 470 UR - https://doi.org/10.1038/nature09732 DO - 10.1038/nature09732 ID - Inuzuka2011 ER - TY - JOUR AU - Ren, H. AU - Koo, J. AU - Guan, B. AU - Yue, P. AU - Deng, X. AU - Chen, M. PY - 2013 DA - 2013// TI - The E3 ubiquitin ligases β-TrCP and FBXW7 cooperatively mediates GSK3-dependent mcl-1 degradation induced by the Akt inhibitor API-1, resulting in apoptosis JO - Mol Cancer VL - 12 UR - https://doi.org/10.1186/1476-4598-12-146 DO - 10.1186/1476-4598-12-146 ID - Ren2013 ER - TY - JOUR AU - Jin, J. AU - Ang, X. L. AU - Ye, X. AU - Livingstone, M. AU - Harper, J. W. PY - 2008 DA - 2008// TI - Differential roles for checkpoint kinases in DNA damage-dependent degradation of the Cdc25A protein phosphatase JO - J Biol Chem VL - 283 UR - https://doi.org/10.1074/jbc.M802474200 DO - 10.1074/jbc.M802474200 ID - Jin2008 ER - TY - JOUR AU - Loveless, T. B. AU - Topacio, B. R. AU - Vashisht, A. A. AU - Galaang, S. AU - Ulrich, K. M. AU - Young, B. D. PY - 2015 DA - 2015// TI - DNA damage regulates translation through β-TRCP targeting of CReP JO - PLoS Genet VL - 11 UR - https://doi.org/10.1371/journal.pgen.1005292 DO - 10.1371/journal.pgen.1005292 ID - Loveless2015 ER - TY - JOUR AU - Winston, J. T. AU - Koepp, D. M. AU - Zhu, C. AU - Elledge, S. J. AU - Harper, J. W. PY - 1999 DA - 1999// TI - A family of mammalian F-box proteins JO - Curr Biol VL - 9 UR - https://doi.org/10.1016/S0960-9822(00)80021-4 DO - 10.1016/S0960-9822(00)80021-4 ID - Winston1999 ER - TY - JOUR AU - Frescas, D. AU - Pagano, M. PY - 2008 DA - 2008// TI - Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer JO - Nat Rev Cancer VL - 8 UR - https://doi.org/10.1038/nrc2396 DO - 10.1038/nrc2396 ID - Frescas2008 ER - TY - JOUR AU - Thomas, Y. AU - Coux, O. AU - Baldin, V. PY - 2011 DA - 2011// TI - βTrCP-dependent degradation of CDC25B phosphatase at the metaphase-anaphase transition is a pre-requisite for correct mitotic exit JO - Cell Cycle VL - 9 UR - https://doi.org/10.4161/cc.9.21.13593 DO - 10.4161/cc.9.21.13593 ID - Thomas2011 ER - TY - JOUR AU - Grigoreva, T. A. AU - Tribulovich, V. G. AU - Garabadzhiu, A. V. AU - Melino, G. AU - Barlev, N. A. PY - 2015 DA - 2015// TI - The 26S proteasome is a multifaceted target for anti-cancer therapies JO - Oncotarget VL - 6 UR - https://doi.org/10.18632/oncotarget.4619 DO - 10.18632/oncotarget.4619 ID - Grigoreva2015 ER - TY - STD TI - Dreyling M, Ferrero S, on behalf of European Mantle Cell Lymphoma Network. The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive ? Haematologica. 2016;101:104–14. ID - ref37 ER - TY - JOUR AU - Mohanty, A. AU - Sandoval, N. AU - Das, M. AU - Pillai, R. AU - Chen, L. AU - Chen, R. W. PY - 2016 DA - 2016// TI - CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma JO - Oncotarget VL - 7 ID - Mohanty2016 ER - TY - JOUR AU - Rahal, R. AU - Frick, M. AU - Romero, R. AU - Korn, J. M. AU - Kridel, R. AU - Chan, F. C. PY - 2014 DA - 2014// TI - Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma JO - Nat Med VL - 20 UR - https://doi.org/10.1038/nm.3435 DO - 10.1038/nm.3435 ID - Rahal2014 ER - TY - JOUR AU - Ma, J. AU - Lu, P. AU - Guo, A. AU - Cheng, S. AU - Zong, H. AU - Martin, P. PY - 2014 DA - 2014// TI - Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells JO - Br J Haematol VL - 166 UR - https://doi.org/10.1111/bjh.12974 DO - 10.1111/bjh.12974 ID - Ma2014 ER - TY - JOUR AU - Saba, N. S. AU - Liu, D. AU - Herman, S. E. AU - Underbayev, C. AU - Tian, X. AU - Behrend, D. PY - 2016 DA - 2016// TI - Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma JO - Blood VL - 128 UR - https://doi.org/10.1182/blood-2015-11-681460 DO - 10.1182/blood-2015-11-681460 ID - Saba2016 ER - TY - JOUR AU - Acosta-Alvear, D. AU - Cho, M. Y. AU - Wild, T. AU - Buchholz, T. J. AU - Lerner, A. G. AU - Simakova, O. PY - 2015 DA - 2015// TI - Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits JO - elife VL - 4 UR - https://doi.org/10.7554/eLife.08153 DO - 10.7554/eLife.08153 ID - Acosta-Alvear2015 ER - TY - JOUR AU - Richardson, P. G. AU - Chanan-Khan, A. A. AU - Lonial, S. AU - Krishnan, A. Y. AU - Carroll, M. P. AU - Alsina, M. PY - 2011 DA - 2011// TI - Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study JO - Br J Haematol VL - 153 UR - https://doi.org/10.1111/j.1365-2141.2011.08664.x DO - 10.1111/j.1365-2141.2011.08664.x ID - Richardson2011 ER - TY - JOUR AU - Nakashima, T. AU - Ishii, T. AU - Tagaya, H. AU - Seike, T. AU - Nakagawa, H. AU - Kanda, Y. PY - 2010 DA - 2010// TI - New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells JO - Clin Cancer Res VL - 16 UR - https://doi.org/10.1158/1078-0432.CCR-09-3112 DO - 10.1158/1078-0432.CCR-09-3112 ID - Nakashima2010 ER - TY - JOUR AU - Ishii, T. AU - Seike, T. AU - Nakashima, T. AU - Juliger, S. AU - Maharaj, L. AU - Soga, S. PY - 2012 DA - 2012// TI - Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib JO - Blood Cancer J VL - 2 UR - https://doi.org/10.1038/bcj.2012.13 DO - 10.1038/bcj.2012.13 ID - Ishii2012 ER - TY - JOUR AU - Heimberger, T. AU - Andrulis, M. AU - Riedel, S. AU - Stuhmer, T. AU - Schraud, H. AU - Beilhack, A. PY - 2013 DA - 2013// TI - The heat shock transcription factor 1 as a potential new therapeutic target in multiple myeloma JO - Br J Haematol VL - 160 UR - https://doi.org/10.1111/bjh.12164 DO - 10.1111/bjh.12164 ID - Heimberger2013 ER - TY - JOUR AU - Bustany, S. AU - Cahu, J. AU - Descamps, G. AU - Pellat-Deceunynck, C. AU - Sola, B. PY - 2015 DA - 2015// TI - Heat shock factor 1 is a potent therapeutic target for enhancing the efficacy of treatments for multiple myeloma with adverse prognosis JO - J Hematol Oncol VL - 8 UR - https://doi.org/10.1186/s13045-015-0135-3 DO - 10.1186/s13045-015-0135-3 ID - Bustany2015 ER - TY - STD TI - Shah SP, Nooka AK, Jaye DL, Bahlis NJ, Lonial S, Boise LH. Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation. Oncotarget. 2016, in press. doi: 10.18632/oncotarget.10847. ID - ref48 ER - TY - JOUR AU - Pommier, Y. PY - 2006 DA - 2006// TI - Topoisomerase I inhibitors: camptothecins and beyond JO - Nat Rev Cancer VL - 6 UR - https://doi.org/10.1038/nrc1977 DO - 10.1038/nrc1977 ID - Pommier2006 ER - TY - JOUR AU - Tsvetkov, P. AU - Mendillo, M. L. AU - Zhao, J. AU - Carette, J. E. AU - Merrill, P. H. AU - Cikes, D. PY - 2015 DA - 2015// TI - Compromising the 19S proteasome complex protects cells from reduced flux through the proteasome JO - elife VL - 4 UR - https://doi.org/10.7554/eLife.08467 DO - 10.7554/eLife.08467 ID - Tsvetkov2015 ER - TY - JOUR AU - Oerlemans, R. AU - Franke, N. E. AU - Assaraf, Y. G. AU - Cloos, J. AU - Zantwijk, I. AU - Berkers, C. R. PY - 2008 DA - 2008// TI - Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein JO - Blood VL - 112 UR - https://doi.org/10.1182/blood-2007-08-104950 DO - 10.1182/blood-2007-08-104950 ID - Oerlemans2008 ER - TY - JOUR AU - Lichter, D. I. AU - Danaee, H. AU - Pickard, M. D. AU - Tayber, O. AU - Sintchak, M. AU - Shi, H. PY - 2012 DA - 2012// TI - Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapse multiple myeloma treated with bortezomib or dexamethasone JO - Blood VL - 120 UR - https://doi.org/10.1182/blood-2012-05-426924 DO - 10.1182/blood-2012-05-426924 ID - Lichter2012 ER - TY - JOUR AU - Vangala, J. R. AU - Dudem, S. AU - Jain, N. AU - Kalivendi, S. V. PY - 2014 DA - 2014// TI - Regulation of PSMB5 protein and β subunits of mammalian proteasome by constitutively activated signal transducer and activator of transcription 3 (STAT3): potential role in bortezomib-mediated anticancer therapy JO - J Biol Chem VL - 289 UR - https://doi.org/10.1074/jbc.M113.542829 DO - 10.1074/jbc.M113.542829 ID - Vangala2014 ER - TY - JOUR AU - Rouette, A. AU - Trofimov, A. AU - Haberl, D. AU - Boucher, G. AU - Lavallée, V. P. AU - D'Angelo, G. PY - 2016 DA - 2016// TI - Expression of immunoproteasome genes is regulated by cell-intrinsic and-extrinsic factor in human cancers JO - Sci Rep VL - 6 UR - https://doi.org/10.1038/srep34019 DO - 10.1038/srep34019 ID - Rouette2016 ER - TY - JOUR AU - Kreso, A. AU - Dick, J. E. PY - 2014 DA - 2014// TI - Evolution of the cancer stem cell model JO - Cancer Stem Cell VL - 14 UR - https://doi.org/10.1016/j.stem.2014.02.006 DO - 10.1016/j.stem.2014.02.006 ID - Kreso2014 ER - TY - JOUR AU - Vlashi, E. AU - Lagadec, C. AU - Chan, M. AU - Frohnen, P. AU - McDonald, A. J. AU - Pajonk, F. PY - 2013 DA - 2013// TI - Targeted elimination of breast cancer cells with low proteasome activity is sufficient for tumor regression JO - Breast Cancer Res Treat VL - 141 UR - https://doi.org/10.1007/s10549-013-2688-6 DO - 10.1007/s10549-013-2688-6 ID - Vlashi2013 ER - TY - JOUR AU - Lagadec, C. AU - Vlashi, E. AU - Bhuta, S. AU - Lai, C. AU - Mischel, P. AU - Werner, M. PY - 2014 DA - 2014// TI - Tumor cells with low proteasome subunit expression predict overall survival in head and neck cancer patients JO - BMC Cancer VL - 14 UR - https://doi.org/10.1186/1471-2407-14-152 DO - 10.1186/1471-2407-14-152 ID - Lagadec2014 ER - TY - JOUR AU - Ahmed, M. AU - Zhang, L. AU - Nomie, K. AU - Lam, L. AU - Wang, M. PY - 2016 DA - 2016// TI - Gene mutations and actionable genetic lesions in mantle cell lymphoma JO - Oncotarget VL - 7 UR - https://doi.org/10.18632/oncotarget.10716 DO - 10.18632/oncotarget.10716 ID - Ahmed2016 ER -